Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      China Sorafenib Market Research Report 2021-2025 Featuring Bayer AG (Nexavar) & Jiangxi Shanxiang Pharmaceutical

      Research and Markets Logo

      News provided by

      Research and Markets

      Dec 31, 2021, 10:15 ET

      Share this article

      Share this article


      DUBLIN, Dec. 31, 2021 /PRNewswire/ -- The "Research Report on China's Sorafenib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

      According to the publisher's market research, the sales value of China's sorafenib market continued to grow from 2016 to 2019. In 2020, the sales value declined to approximately USD406 million due to COVID-19, but the CAGR from 2016 to 2020 was still up to 22.3%.

      As of August 2021, besides Bayer's sorafenib product, only generic versions of Jiangxi Shanxiang Pharmaceutical and Chongqing Yaoyou Pharmaceutical have been officially marketed in the Chinese market. Some other companies such as Yabao Pharmaceutical Group and CSPC Ouyi Pharmaceutical have filed applications for the marketing of generic sorafenib drugs.

      In September 2020, The China National Intellectual Property Administration issued an invalidation request review decision (No. 46292), declaring that Bayer's patent CN200680007187.1 for sorafenib mesylate in China was invalid. The invalidation petitioner was Chongqing Yaoyou Pharmaceutical. With the invalidation of Bayer's patent applications related to sorafenib, more generic sorafenib drugs from local Chinese pharmaceutical companies will be launched in China.

      In China, the incidence of primary liver cancer ranked fifth among that of malignant tumors in 2020, with 410,000 new cases, including 303,000 cases in men; the mortality rate of the cancer ranked second with 391,000 deaths in 2020, a mortality rate of 17.2/100,000 of the total population.

      From 2016 to 2020, global average annual incidence of primary liver cancer was 995,000 cases, with Asia 732,000 cases, accounting for 73.6%, and China 423,000 cases, accounting for 42.5%. The high incidence of liver cancer in China is highly correlated with the fact that China is a country with high prevalence of hepatitis B, environmental pollution, and some spirits-addicted residents.

      Liver cancer is a common malignant tumor in China. Liver cancer starts insidiously but progresses rapidly, and by the time it is detected, it is often at an advanced stage, making the treatment of surgery ineffective. Moreover, radiotherapy is of little use in treating liver cancer.

      Therefore, targeted drug therapy becomes the standard treatment for patients with advanced liver cancer. Sorafenib is the world's first multi-targeted, multi-kinase inhibitor for the treatment of liver cancer.

      It can directly suppress tumor growth by inhibiting RAF/MEK/ERK signaling pathway, and indirectly suppress tumor growth by blocking the formation of tumor neovascularization through inhibiting VEGFR and PDGFR. Therefore, it is the first-line drug used for the treatment of advanced primary liver cancer.

      Sorafenib is a multi-kinase inhibitor originally developed by Bayer AG with the trade name of Nexavar. Sorafenib was approved for marketing by the FDA of U.S. in December 2005 and approved by China in August 2006. In 2017, Bayer's sorafenib was included in the category B of China's national medical insurance catalog after a negotiated price reduction of about 70%, and the price after inclusion in medical insurance is about CNY200 (approximately USD30.8) per tablet. From 2018 to 2021, Bayer AG continues to reduce the price of sorafenib in the Chinese market.

      For Bayer, as more generic drugs are approved and marketed, the market share of Nexavar in China will gradually decline. Bayer is expected to stop the decline of Nexavar's market share through measures such as price cuts.

      The publisher expects that from 2021 to 2025, the average sales price of sorafenib in China will decline due to fierce competition while both sales volume and value will continue to rise.

      Topics Covered:

      • Impact of COVID-19 on China's Sorafenib Market
      • Development Environment of Sorafenib in China
      • Sales Volume of Sorafenib in China
      • Sales Volume and Value of Sorafenib in China by Region
      • Major Sorafenib Manufacturers in China and Their Market Shares
      • Sales Price of Sorafenib in China
      • Prospects of China's Sorafenib Market, 2021-2025

      Key Topics Covered:

      1 Relevant Concept of Sorafenib
      1.1 Indications of Sorafenib
      1.2 Development of China's Sorafenib Market
      1.3 Governmental Approval of Sorafenib in China
      1.4 The Impact of COVID-19 on China's Sorafenib Market

      2 Sales of Sorafenib in China, 2016-2020
      2.1 Sales Value
      2.1.1 Sales Value in China
      2.1.2 Sales Value in China by Region
      2.2 Sales Volume
      2.2.1 Sales Volume in China
      2.2.2 Sales Volume in China by Region
      2.3 Sales of Sorafenib in China by Dosage Form, 2016-2020
      2.3.1 Tablets
      2.3.2 Other Dosage Forms

      3 Analysis of Major Sorafenib Manufacturers in China, 20203.1 Analysis of Market Share
      3.1.1 Market Share of Manufacturers by Sales Value
      3.1.2 Market Share of Manufacturers by Sales Volume
      3.2 Bayer AG
      3.2.1 Company Profile
      3.2.2 Sales of Sorafenib in China
      3.3 Jiangxi Shanxiang Pharmaceutical Co., Ltd.
      3.3.1 Company Profile
      3.3.2 Sales of Sorafenib in China

      4 Sales Price of Sorafenib of Different Companies in China, 2020-20214.1 Bayer AG (Nexavar)
      4.2 Jiangxi Shanxiang Pharmaceutical Co., Ltd. (Ligesitai)

      5 Prospects of China's Sorafenib Market, 2021-20255.1 Influencing Factors for the Market Development
      5.1.1 The Impact of COVID-19 on the Market
      5.1.2 Market Drivers and Opportunities
      5.1.3 Market Threats and Challenges
      5.2 Forecast on Market Size
      5.3 Forecast on Market Trend

      Companies Mentioned

      • Bayer AG (Nexavar)
      • Jiangxi Shanxiang Pharmaceutical Co., Ltd. (Ligesitai)

      For more information about this report visit https://www.researchandmarkets.com/r/kiowxr

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]  

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716


      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.